S-Amlodipine: An Isomer with Difference-Time to Shift from Racemic Amlodipine.
Int J Hypertens
; 2018: 8681792, 2018.
Article
em En
| MEDLINE
| ID: mdl-29887996
ABSTRACT
Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Observational_studies
Idioma:
En
Revista:
Int J Hypertens
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Índia